The increasing demand for innovative techniques arises from the lack of safe, effective, and patient-friendly therapies for neurodegenerative disorders. With this objective in mind, the chapters of the book are structured to offer a thorough insight into recent advancements in utilizing the zebrafish (ZF) as a model for studying Parkinson’s disease (PD). This book aims to present readers with a comprehensive understanding of the clinical application of the ZF model in treating PD, encompassing the latest developments, challenges, safety considerations, toxicity issues, regulatory aspects, future potential, and limitations. Individuals in academia, the scientific community, business, and education seeking a more effective approach to target the brain stand to benefit from this resource.Key FeaturesProvides a comparative perspective of the zebrafish–Parkinson’s disease modelHighlights the restrictions of available medicinesDescribes biochemical and histopathological characteristics, advantages, and disadvantages of this modelEmphasizes distinct facets of histopathologyPresents advances and developments of the future potential perspectives
Les mer
The increasing demand for innovative techniques arises from the lack of effective, and patient-friendly therapies for neurodegenerative disorders. With this objective in mind, the chapters of the book are structured to offer a thorough insight into recent advancements in utilizing the Zebrafish as a model for studying Parkinson's disease.
Les mer
SECTION-I: FROM AQUARIUM TO LAB: THE RISE OF ZEBRAFISH AS A MODEL ORGANISM. 1. General Methods For Zebrafish Care. 2. Breeding of Zebrafish and its life cycle. 3. Neurobehavioral assessment of Zebrafish. 4. Cellular and Genetic Methods in Zebrafish. 5. Repeated blood sampling from an adult Danio rerio. 6. Zebrafish Culture. 7. Calcium Imaging of Neuronal Activity in Free-Swimming Larval Zebrafish. 8. Anesthesia, Analgesia, and Euthanasia of the Laboratory Zebrafish. 9. Zebrafish Guidelines, Policies and Regulations in Research. SECTION-II: ZEBRAFISH AS A MODEL OF PARKINSON’S DISEASE.10. The Role of Neurotransmitters in the Pathophysiology of Parkinson's Disease. 11. Diagnosis and Biomarkers of PD. 12. Parkinson's Disease Models Pros and Cons. 13. Pharmacotherapy of PD and their limitations. 14. Induction and VALIDATION OF ZF model of PD. 15. Zebra fish as a model for a novel Parkinson’s disease protective natural Product. 16. Zebrafish model for studying microbiome associated Parkinson’s Disease. 17. Transgenic zebrafish reporter lines for in vivo studying of Parkinson’s disease. 18. Interplay of neurodenegrative disorders in zebrafish: unlocking the mystery. 19. Smart Capsule and Edible Bird's Nest: Charting New Frontiers in Parkinson’s Disease Defense-An Experimental Protocol Perspective. 20. Zebrafish Model for Drug Discovery and Screening.
Les mer

Produktdetaljer

ISBN
9781032515779
Publisert
2024-10-04
Utgiver
Vendor
CRC Press
Vekt
453 gr
Høyde
297 mm
Bredde
210 mm
Aldersnivå
P, 06
Språk
Product language
Engelsk
Format
Product format
Innbundet
Antall sider
298

Redaktør

Biographical note

Wael Mohamed Yousef Mohamed

BBCH (Egypt), MMSc (Egypt), MD/PhD (USA)

Dr. Mohamed, a Physician Neuroscientist, earned his PhD from PSU in the USA and currently holds the position of Associate Professor at IIUM Medical School in Malaysia. With an extensive background, Dr. Mohamed has been invited to deliver over 150 lectures both domestically and internationally. His contributions to Neuroscience/Psychiatry are notable, with the publication of more than 100 peer-reviewed papers, boasting an h-index of 20. Furthermore, Dr. Mohamed serves as an editor for Frontiers in Neurology and PLOS-ONE Journals, where he has contributed to various journal special issues on brain disorders. In the realm of book editing, he is actively involved with Springer, CRC, and Cambridge in the field of neuroscience. His research endeavors have attracted numerous grants from esteemed national and international organizations, including IBRO, ISN, MJF, STDF, FRGS, and INDO-ASEAN, amounting to a total research funding of half a million US$. Notably, he is the founder and chair of the AfrAbia-PD-Genomic Consortium.